IL17A and Alzheimer disease: Indeed, rifampicin treatment reduced PM-induced type 17 inflammation in AD-like keratinocytes, with decreased mRNA (IL-17A, IL-23A, IL-1β, and IL-6) and protein (IL-17A, IL-1β, and IL-6) levels of type 17 cytokines after PM treatment in rifampicin-treated keratinocytes (Figures 4C–I).